Abstract library

29 results for "portal vein".
#1295 Intra-Operative Portal Vein Insulin Assay Combined with Occlusion of the Pancreas for Complicated Pancreatogenous Hypoglycemia
Introduction: Pancreatogenous hypoglycemia is a rare endocrine disorder. The precise localization of hypersecreting tissue and determination of complete resection are two main challenges for complicated pancreatogenous hypoglycemia, such as multiple endocrine neoplasia syndromes type-1 (MEN-1) and nesidioblastosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Surgical treatment
Presenting Author: Yang Zhiying
Authors: Yang Z, Tan H, Sun Y, Si S, ...
#1901 Portal Hypertension-Related Digestive Hemorrhage in Patients with Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (pNET) can cause portal hypertension (PHT)
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Clinical cases/reports
Presenting Author: Nelly Muller
#839 Complete Mesenterial Venous Obstruction – A Clinical Syndrome Unique to Neuroendocrine Neoplasms of the Small Bowel
Introduction: Neuroendocrine neoplasms of the small bowel are mostly advanced or metastasized at diagnosis. Metastases typically occur in the mesenteric root and liver.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Others
Presenting Author: Prof. Dieter Hörsch
Keywords: NET
#2158 ALPPS as a Technique to Minimize Small For Size Syndrome after Major Hepatectomy for Neuroendocrine Tumour Metastases.
Introduction: Liver resection has emerged as an effective treatment for secondary liver neuroendocrine tumours. “Associated liver partition and portal vein ligation for staged hepatectomy” (ALPPS) allows resection of liver tumours in 2 steps.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Michail Pizanias
#1047 Unresectable Gastrointestinal Neuroendocrine Liver Metastases Treated by Liver-Directed Therapies
Introduction: Hepatic metastases develop in 85% of patients with GI neuroendocrine tumors. Liver-directed therapies allows for manageable microinvasive treatments able to improve the benefit and reduce the toxicity.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Lingxiao J Liu
Authors: Liu L J, Xin B, Ji Y, Yan Z, ...
#3064 ALPPS for Neuroendocrine Liver Metastases Not Suitable for Conventional Hepatic Resection - Interim Analysis of the International ALPPS Registry
Introduction: Surgery is the most effective treatment option for neuroendocrine liver metastases (NELM). However, the majority of patients with NELM do not have disease that is resectable using conventional methods. Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) is a relatively novel two-stage strategy in hepatic surgery.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Surgical treatment and Ablative Therapies
Presenting Author: Dr Ashley Clift
#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?
Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Surgical treatment
Presenting Author: Dr Frédéric Dumont
#984 Superior Mesenteric Vein Stenting for Management of Complications of Mesenteric Desmoplasia in Midgut Neuroendocrine Tumors
Introduction: Mesenteric fibrosis is a cause of morbidity and mortality in patients with midgut neuroendocrine tumors (mNETs). It may cause occlusion of the superior mesenteric vein (SMV), which can be associated with development ascites and mesenteric and small bowel varices (SBVs) leading to occult gastrointestinal (GI) bleeding.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Keval B Naik
#922 Comparison of the Novel Cell Detector Method with Cell Search Technology in the Isolation of Circulating Tumor Cells in Neuroendocrine Tumors
Introduction: Circulating Tumor Cells (CTCs) have been detected in patients with neuroendocrine tumors (NET) using the CellSearch platform. Their presence is associated with a worse clinical outcome but less than 50% patients have detectable cells. The GILUPI Cell Detector is an EpCAM coated wire that is inserted into a vein and has been developed to increase capture of CTCs.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Biomarkers
Presenting Author: Dr Dalvinder Mandair
Authors: Mandair D, Ensell L, Vesely C, Lowe H, ...
#1006 The Use of Endoluminal Stents to Overcome Vascular Obstruction Arising from Mesenteric and Retroperitoneal Neuroendocrine Metastases
Introduction: Gastroenteropancreatic neuroendocrine tumors (GEP-NET) often metastasise to lymph nodes. Nodal metastases from neuroendocrine tumors in the distal small intestine commonly (>50%) develop in the mesentery and are often centred at the mesenteric root surrounding the major vessels supplying the bowel. Compression of these vessels, by the nodes or associated fibrosis, can lead to severe symptoms such as pain (secondary to bowel ischaemia ), ascites (from superior mesenteric vein obstruction) and bowel perforation. In view of the often indolent nature of GEP-NET, symptoms from lymph node masses can persist for years, causing significant morbidity and early mortality.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Dr Alan Anthoney
Authors: Anthoney A, Patel J, Kamposioras K, ...